NL
DE
Renske van den Bijgaart and Gosse Adema, theme Cancer development and immune defence received a grant from Villa Joep, entitled “Bifunctional anti-GD2 antibodies co-targeting innate immune checkpoints to improve immunotherapy of Neuroblastoma”.
In this grant the, ROI research team will develop novel bifunctional monoclonal antibody formats that target the GD2 tumor-associated antigen on Neuroblastoma (NBL) and locally activate the immune system.
Renske van den Bijgaart and Gosse Adema both are from the Radiotherapy & OncoImmunology (ROI) laboratory (Department of Radiation Oncology) and in collaboration with the Prinses Maxima Center (Peter Hoogerbrugge) they received this Villa Joep grant of 410K Euro.
-
Want to know more about these subjects? Click on the buttons below for more news.
Related news items
T cell immunity is directed by tetraspanin CD53
5 July 2022 T cells are immune cells that are key for the defense against pathogens and cancer. T cells depend on the membrane protein CD45 to initiate T cell receptor signaling, but how CD45 is controlled at the molecular level is poorly understood. read more
A single protein complex balances the very first lineage decision of cells in human: towards foetus or placenta
21 June 2022 The international group of researchers spearheaded by Dick Zijlmans and Hendrik Marks together with colleagues from KU Leuven, examined which proteins are associated with the chromatin and how this affects gene transcription. read more
2.5 million Euros for cancer research into ovarian cancer and immunotherapy
15 April 2021 The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period. read more
